Lewis DF. Quantitative structure-activity relationships (QSARs) for substrates of
human cytochromes P450 CYP2 family enzymes. Toxicol In Vitro 2004;18:89–97.
Lewis DF. Human P450s in the metabolism of drugs: molecular modelling of enzyme–
substrate interactions. Expert Opin Drug Metab Toxicol 2005;1:5–8.
Lewis DF, Ito Y, Goldfarb PS. Investigating human P450s involved in drug metabolism
via homology with high-resolution P450 crystal structures of the CYP2C subfamily.
Curr Drug Metab 2006;7:589–598.
Liebler DC, Guengerich FP. Elucidating mechanisms of drug-induced toxicity. Nat Rev
Drug Discov 2005;4:410–420.
Lim HK, Stellingweif S, Sisenwine S, Chan KW. Rapid drug metabolite profiling using
fast liquid chromatography, automated multiple-stage mass spectrometry and
receptor-binding. J Chromatogr A 1999;831:227–241.
Lin JH. Applications and limitations of interspecies scaling andin vitroextrapolation in
pharmacokinetics. Drug Metab Dispos 1998;26:1202–1212.
Lin JH, Wong BK. Complexities of glucuronidation affecting in vitro–in vivo
extrapolation. Curr Drug Metab 2002;3:623–646.
Long A, Walker JD. Quantitative structure-activity relationships for predicting
metabolism and modeling cytochrome p450 enzyme activities. Environ Toxicol
Chem 2003;22:1894–1899.
Margolis JM, Obach RS. Impact of nonspecific binding to microsomes and
phospholipid on the inhibition of cytochrome P4502 D6: implications for relating
in vitroinhibition data toin vivodrug interactions. Drug Metab Dispos 2003;31:
606–611.
Masubuchi Y, Igarashi S, Suzuki T, Horie T, Narimatsu S. Imipramine-induced
inactivation of a cytochrome P450 2D enzyme in rat liver microsomes: in relation to
covalent binding of its reactive intermediate. J Pharmacol Exp Ther 1996;279:724–
731.
Mays DC, Hilliard JB, Wong DD, Chambers MA, Park SS, Gelboin HV, Gerber N.
Bioactivation of 8-methoxypsoralen and irreversible inactivation of cytochrome
P-450 in mouse liver microsomes: modification by monoclonal antibodies, inhibition
of drug metabolism and distribution of covalent adducts. J Pharmacol Exp Ther
1990;254:720–731.
Mays DC, Pawluk LJ, Apseloff G, Davis WB, She ZW, Sagone AL, Gerber N.
Metabolism of phenytoin and covalent binding of reactive intermediates in activated
human neutrophils. Biochem Pharmacol 1995;50:367–380.
Miners JO, Knights KM, Houston JB, Mackenzie PI.In vitro–in vivocorrelation for
drugs and other compounds eliminated by glucuronidation in humans: pitfalls and
promises. Biochem Pharmacol 2006;71:1531–1539.
Miners JO, Smith PA, Sorich MJ, McKinnon RA, Mackenzie PI. Predicting human
drug glucuronidation parameters: application of in vitroandin silicomodeling
approaches. Annu Rev Pharmacol Toxicol 2004;44:1–25.
Mutlib A, Lam W, Atherton J, Chen H, Galatsis P, Stolle W. Application of stable
isotope labeled glutathione and rapid scanning mass spectrometers in detecting and
characterizing reactive metabolites. Rapid Commun Mass Spectrom 2005;19:3482–
3492.
REFERENCES 257